INDV
Indivior Pharmaceuticals Inc NASDAQ$38.98
Mkt Cap $4.9B
52w Low $10.63
96.5% of range
52w High $40.02
50d MA $31.98
200d MA $29.30
P/E (TTM)
22.4x
EV/EBITDA
15.3x
P/B
—
Debt/Equity
-3.6x
ROE
-214.3%
P/FCF
-48.2x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$31.98
200d MA
$29.30
Avg Volume
2.4M
About
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.64 | 0.96 | +50.0% | 34.15 | +5.3% | +7.7% | +10.3% | — | — | — | — | — |
| Feb 26, 2026 | BMO | 0.65 | 0.82 | +26.2% | 33.63 | +2.6% | +0.2% | -2.7% | -4.9% | -8.2% | -4.4% | -14.4% | — |
| Oct 30, 2025 | BMO | 0.38 | 0.72 | +89.5% | 25.24 | +18.9% | +15.4% | +16.4% | +23.6% | +26.8% | +27.0% | +33.1% | — |
| Jul 31, 2025 | BMO | 0.26 | 0.51 | +96.2% | 17.40 | +19.9% | +16.1% | +21.0% | +22.0% | +25.3% | +26.4% | +41.4% | — |
| Apr 24, 2025 | BMO | 0.22 | 0.41 | +86.4% | 9.45 | +10.1% | +13.9% | +22.3% | +22.4% | +24.3% | +21.8% | +25.2% | — |
| Feb 20, 2025 | BMO | 0.32 | 0.32 | +0.0% | 10.91 | -17.7% | -17.6% | -22.5% | -24.4% | -24.3% | -21.4% | -7.4% | — |
| Oct 24, 2024 | BMO | 0.31 | 0.54 | +74.2% | 8.56 | +6.5% | +2.5% | +5.1% | +4.2% | +7.0% | +8.6% | +27.2% | — |
| Jul 25, 2024 | BMO | 0.40 | 0.44 | +10.0% | 10.88 | +16.5% | +20.3% | +17.6% | +19.9% | +25.5% | +26.4% | +14.4% | — |
| Apr 25, 2024 | BMO | 0.42 | 0.37 | -11.9% | 18.81 | -4.6% | -8.3% | -6.5% | -4.7% | -6.6% | -6.3% | -1.8% | — |
| Feb 22, 2024 | BMO | 0.28 | 0.43 | +53.6% | 17.50 | +14.6% | +21.7% | +21.6% | +22.3% | +27.1% | +25.1% | +18.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.44 | $36.22 | +2.2% | -2.5% | -4.1% | -5.1% | -7.2% | -8.2% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.13 | $29.68 | +1.9% | +0.8% | +7.1% | +9.9% | +10.0% | +9.4% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.24 | $30.00 | +18.9% | +15.4% | +16.4% | +23.6% | +26.8% | +27.0% |
| Aug 27 | Craig-Hallum | Maintains | Buy → Buy | — | $24.46 | $24.90 | +1.8% | -0.4% | -2.4% | -0.7% | +0.6% | +0.9% |
| Jun 30 | Craig-Hallum | Maintains | Buy → Buy | — | $13.95 | $14.19 | +1.7% | +5.7% | +5.1% | +10.4% | +10.5% | +11.5% |
| Mar 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.01 | $9.80 | -2.1% | -1.2% | -3.1% | -4.9% | -2.4% | -2.5% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.77 | $9.16 | +4.4% | +2.6% | +1.7% | +4.4% | +6.0% | +2.7% |
| Oct 11 | Craig-Hallum | Maintains | Buy → Buy | — | $7.98 | $7.63 | -4.4% | -6.5% | -1.0% | +0.3% | +2.0% | +7.6% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.98 | $7.63 | -4.4% | -6.5% | -1.0% | +0.3% | +2.0% | +7.6% |
| Sep 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.62 | $9.72 | +1.0% | +2.9% | -0.8% | -1.1% | +1.6% | +0.6% |
Recent Filings
8-K · 8.01
!! High
Indivior Pharmaceuticals Inc -- 8-K 8.01: Material Event / Announcement
Indivior Pharmaceuticals disclosed a material event in an 8-K filing, though the specific announcement details are contained in the attached press release exhibit.
May 4
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
INDV secured a $75 million financing agreement, providing crucial capital for operations and growth that should strengthen its balance sheet and reduce near-term liquidity concerns for investors.
Mar 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Indivior increased debt financing by $50M and granted a $50M overallotment option, suggesting strong investor demand but raising leverage concerns for shareholders.
Mar 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Indivior is raising up to $260 million in convertible debt maturing 2031, diluting existing shareholders but providing liquidity and refinancing flexibility.
Mar 12
8-K
Indivior Pharmaceuticals, Inc. -- 8-K Filing
Indivior reported Q4 and full-year 2025 financial results with a business update, providing investors insight into the pharmaceutical company's recent operational performance and forward guidance.
Feb 26
Data updated apr 25, 2026 3:33pm
· Source: massive.com